Financial Performance - For the six months ended September 30, 2024, the group reported revenue of HKD 41,688,000, a slight increase of 0.93% compared to HKD 41,305,000 for the same period in 2023[3] - Gross profit for the same period was HKD 20,393,000, representing a gross margin of approximately 48.9%[3] - The net profit attributable to equity shareholders for the period was HKD 3,439,000, compared to a loss of HKD 87,000 in the previous year[3] - Basic and diluted earnings per share for the period were HKD 0.42, reflecting a significant improvement from the previous year[3] - Revenue from medical consumables reached HKD 30,014,000, up from HKD 26,497,000 in 2023, indicating a growth of about 13.5%[28] - The company reported a total of HKD 2,348,000 in other income for the six months ended September 30, 2024, compared to HKD 997,000 in 2023, reflecting a significant increase of approximately 135.5%[30] - The company's profit for the six months ended September 30, 2024, rose by approximately HKD 600,000 to HKD 3,400,000, attributed to government subsidies received amounting to approximately HKD 1,550,000[65] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 103,793,000, slightly down from HKD 104,195,000 as of March 31, 2024[5] - The group’s total liabilities decreased to HKD 8,985,000 from HKD 11,219,000, indicating improved financial stability[7] - The company’s equity attributable to shareholders increased to HKD 104,765,000 from HKD 103,326,000, showing a growth in shareholder value[7] - The company's total liabilities as of September 30, 2024, were HKD 20,266,000, compared to HKD 18,203,000 as of March 31, 2024, indicating an increase of approximately 11.3%[45] - Current liabilities decreased to approximately HKD 9 million from HKD 11.2 million as of March 31, 2024[67] Cash Flow and Management - The net cash generated from operating activities for the six months ended September 30, 2024, was HKD 623,000, compared to a net cash used of HKD 2,764,000 in the same period of 2023[12] - Cash and cash equivalents at the end of the period were HKD 57,884,000, compared to HKD 52,807,000 at the end of the same period in 2023, showing an increase of about 9.8%[12] - The company's total cash and cash equivalents decreased by HKD 2,104,000 during the period, compared to a decrease of HKD 8,278,000 in the same period of 2023, reflecting improved cash flow management[12] - The financing cash outflow for the repayment of lease liabilities was HKD 1,495,000, a decrease from HKD 2,051,000 in the previous year, indicating improved cash management[12] Dividends and Shareholder Information - The company has maintained a stable dividend policy, with a declared dividend of HKD 3,200,000 during the reporting period[10] - The company did not declare an interim dividend for the six months ended September 30, 2024, consistent with the previous year[39] - No interim dividend was declared for the six months ended September 30, 2024, consistent with the previous year[66] - The company reported a total of 8,000,000,000 authorized shares, with 800,000,000 shares issued and fully paid as of September 30, 2024[54] - The number of share options available for grant under the share option scheme increased to 71,940,000 shares, representing 8.99% of the total issued share capital as of September 30, 2024[55] Research and Development - Research and development expenses for the six months ended September 30, 2024, were approximately HKD 1,909,000, up from HKD 1,534,000 in the same period of 2023, indicating a growth of about 24.5%[35] Corporate Governance and Compliance - The company has adopted the corporate governance code and complied with all provisions, with some exceptions noted[90] - The roles of the chairman and CEO are held by the same individual, Ms. Huang, who is responsible for overall strategy and major decisions[92] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring proper oversight[93] - The audit committee reviewed the unaudited consolidated financial statements for the six months ending September 30, 2024, confirming compliance with applicable accounting standards[93] Market Outlook and Strategy - The group plans to continue exploring market expansion opportunities and enhancing product offerings in the upcoming periods[2] - The company maintains an optimistic outlook for the healthcare sector, driven by an aging population and increasing health awareness among Hong Kong citizens[59] - The company plans to further diversify its product offerings and enhance customer service to strengthen its position as a one-stop medical instrument solution provider[59] Risk Management - The company is closely monitoring foreign exchange risks, particularly with transactions settled in HKD, USD, or EUR, and is considering hedging measures[75]
君百延集团(08372) - 2025 - 中期财报